cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2024-4190OPXTFMcardiovascular-4190Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESЦиркулирующие микроРНК и развитие коллатерального кровообращения при хронической окклюзии коронарной артерииCirculating microRNAs and collateral circulation in coronary chronic total occlusionhttps://orcid.org/0000-0003-4765-8021КиселеваА. В.KiselevaA. V.

Киселева Анна Витальевна — к.б.н., руководитель лаборатории молекулярной генетики Института персонализированной терапии и профилактики, в.н.с.

Москва

Moscow

sanyutabe@gmail.comhttps://orcid.org/0000-0002-8395-4146СотниковаЕ. А.SotnikovaE. A.

Сотникова Евгения Андреевна — с.н.с. лаборатории молекулярной генетики.

Москва

Moscow

sotnikova.evgeniya@gmail.comhttps://orcid.org/0000-0001-9844-3122КуценкоВ. А.KutsenkoV. A.

Куценко Владимир Александрович — к.ф.-м.н., с.н.с. лаборатория биостатистики отдела эпидемиологии хронических неинфекционных заболеваний.

Москва

Moscow

vlakutsenko@ya.ruhttps://orcid.org/0000-0003-0723-0493ЖариковаА. А.ZharikovaA. A.

Жарикова Анастасия Александровна — к.б.н., в.н.с. лаборатории молекулярной генетики, старший преподаватель факультета биоинженерии и биоинформатики.

Москва

Moscow

azharikova89@gmail.comhttps://orcid.org/0000-0001-7989-0760ЕршоваА. И.ErshovaA. I.

Ершова Александра Игоревна — д.м.н., руководитель лаборатории клиномики, зам. директора по фундаментальной науке.

Москва

Moscow

alersh@mail.ruhttps://orcid.org/0000-0001-5989-6233МешковА. Н.MeshkovA. N.

Мешков Алексей Николаевич — д.м.н., руководитель Института персонализированной терапии и профилактики.

Москва

Moscow

meshkov@lipidclinic.ruhttps://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

Драпкина Оксана Михайловна — д.м.н., профессор, академик РАН, директор.

Москва

Moscow

odrapkina@gnicpm.ruФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава РоссииNational Medical Research Center for Therapy and Preventive MedicineФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России; ФГБОУ ВО "Московский государственный университет им. М.В. Ломоносова"National Medical Research Center for Therapy and Preventive Medicine; Lomonosov Moscow State University202402102024231041904190Copyright © Киселева А.В., Сотникова Е.А., Куценко В.А., Жарикова А.А., Ершова А.И., Мешков А.Н., Драпкина О.М., 20242024Киселева А.В., Сотникова Е.А., Куценко В.А., Жарикова А.А., Ершова А.И., Мешков А.Н., Драпкина О.М.Kiseleva A.V., Sotnikova E.A., Kutsenko V.A., Zharikova A.A., Ershova A.I., Meshkov A.N., Drapkina O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/4190

Коронарное коллатеральное кровообращение (ККК), формирующееся выше зоны хронической окклюзии коронарной артерии, является альтернативным кровоснабжением ишемизированного миокарда и повышает выживаемость среди пациентов с ишемической бо­лезнью сердца. В связи с этим идентификация новых маркеров, связанных с выраженностью ККК, имеет диагностический потенциал для стратификации пациентов. Показано, что циркулирующие микроРНК (микро рибонуклеиновые кислоты) играют важную роль практически во всех аспектах деятельности сердечно-сосудистой системы, в т.ч. продемонстрирована связь ряда микроРНК с выраженностью ККК. Цель обзора — рассмотрение основных современных исследований, посвященных изучению ассоциации циркулирующих микроРНК и выраженности ККК при наличии хронической окклюзии коронарной артерии у пациентов с ишемической болезнью сердца, с последующим функциональным анализом выявленных микроРНК.

Coronary collateral circulation (CCC) above the coronary chronic total occlusion is an alternative blood supply to the ischemic myocardium and increases survival among patients with coronary artery disease. In this regard, identification of novel markers associated with the CCC severity has diagnostic potential for patient stratification. It has been shown that circulating microRNAs play an important role in almost all cardiovascular aspects, including the association of some microRNAs with the CCC severity. The aim of this review is to consider the main modern studies on association of circulating microRNAs and CCC severity in coronary chronic total occlusion in patients with coronary artery disease, followed by a functional analysis of the identified microRNAs.

микроРНКкоронарное коллатеральное кровообращениехроническая окклюзия коронарной артерииишемическая болезнь сердцаmicroRNAcoronary collateral circulationcoronary chronic total occlusioncoronary artery diseaseReferencesAntonio M, Misganaw TA, Ali M. Global Burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982-3021. doi:10.1016/j.jacc.2020.11.010.Antonio M, Misganaw TA, Ali M. Global Burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982-3021. doi:10.1016/j.jacc.2020.11.010.Бойцов С. А., Погосова Н. В., Аншелес А. А. и др. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):5452. doi:10.15829/1560-4071-2023-5452.Boytsov SA, Pogosova NV, Ansheles AA, et al. Cardiovascular pre­vention 2022. Russian national guidelines. Russian Journal of Car­diology. 2023;28(5):5452. (In Russ.) doi:10.15829/1560-4071-2023-5452.Vural MG, Temel HY, Turunc E, et al. Transcoronary Gradients of Mechanosensitive MicroRNAs as Predictors of Collateral Development in Chronic Total Occlusion. Medicina. 2024;60. doi:10.3390/medicina60040590.Vural MG, Temel HY, Turunc E, et al. Transcoronary Gradients of Mechanosensitive MicroRNAs as Predictors of Collateral Development in Chronic Total Occlusion. Medicina. 2024;60. doi:10.3390/medicina60040590.Zimarino M, D’Andreamatteo M, Waksman R, et al. The dy­namics of the coronary collateral circulation. Nat Rev Cardiol. 2014;11: 191-7. doi:10.1038/nrcardio.2013.207.Zimarino M, D’Andreamatteo M, Waksman R, et al. The dy­namics of the coronary collateral circulation. Nat Rev Cardiol. 2014;11: 191-7. doi:10.1038/nrcardio.2013.207.Hakimzadeh N, Nossent AY, van der Laan AM, et al. Circulating MicroRNAs Characterizing Patients with Insufficient Coronary Collateral Artery Function. PLoS One. 2015;10:e0137035. doi:10.1371/journal.pone.0137035.Hakimzadeh N, Nossent AY, van der Laan AM, et al. Circulating MicroRNAs Characterizing Patients with Insufficient Coronary Collateral Artery Function. PLoS One. 2015;10:e0137035. doi:10.1371/journal.pone.0137035.Hakimzadeh N, Elias J, Wijntjens GWM, et al. Monocytic micro­RNA profile associated with coronary collateral artery function in chronic total occlusion patients. Sci Rep. 2017;7:1532. doi:10.1038/s41598-017-01695-3.Hakimzadeh N, Elias J, Wijntjens GWM, et al. Monocytic micro­RNA profile associated with coronary collateral artery function in chronic total occlusion patients. Sci Rep. 2017;7:1532. doi:10.1038/s41598-017-01695-3.Gao W, Zhang J, Wu R, et al. Integrated Analysis of Angiogenesis Related lncRNA-miRNA-mRNA in Patients With Coronary Chronic Total Occlusion Disease. Front Genet. 2022;13. doi:10.3389/fgene.2022.855549.Gao W, Zhang J, Wu R, et al. Integrated Analysis of Angiogenesis Related lncRNA-miRNA-mRNA in Patients With Coronary Chronic Total Occlusion Disease. Front Genet. 2022;13. doi:10.3389/fgene.2022.855549.Brilakis ES, Mashayekhi K, Tsuchikane E, et al. Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Interven­tion. Circulation. 2019;140:420-33. doi:10.1161/CIRCULATIONAHA.119.039797.Brilakis ES, Mashayekhi K, Tsuchikane E, et al. Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Interven­tion. Circulation. 2019;140:420-33. doi:10.1161/CIRCULATIONAHA.119.039797.Råmunddal T, Hoebers LP, Henriques JPS, et al. Chronic total occlusions in Sweden-a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). PLoS One. 2014;9:e103850. doi:10.1371/journal.pone.0103850.Råmunddal T, Hoebers LP, Henriques JPS, et al. Chronic total occlusions in Sweden-a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). PLoS One. 2014;9:e103850. doi:10.1371/journal.pone.0103850.Fefer P, Knudtson ML, Cheema AN, et al. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol. 2012;59: 991-7. doi:10.1016/j.jacc.2011.12.007.Fefer P, Knudtson ML, Cheema AN, et al. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol. 2012;59: 991-7. doi:10.1016/j.jacc.2011.12.007.Christofferson RD, Lehmann KG, Martin GV, et al. Effect of chronic total coronary occlusion on treatment strategy. Am J Cardiol. 2005;95:1088-91. doi:10.1016/j.amjcard.2004.12.065.Christofferson RD, Lehmann KG, Martin GV, et al. Effect of chronic total coronary occlusion on treatment strategy. Am J Cardiol. 2005;95:1088-91. doi:10.1016/j.amjcard.2004.12.065.Васильев Д. К., Руденко Б. А., Шаноян А. С. и др. Предикторы безуспешной эндоваскулярной реканализации хронических окклюзий коронарного русла. Кардиоваскулярная терапия и профилактика. 2021;20(3):2725. doi:10.15829/1728-8800-2021-2725.Vasiliev DK, Rudenko BA, Shanoyan AS, et al. Predictors of un­successful endovascular recanalization of coronary chronic total occlusion. Cardiovascular Therapy and Prevention. 2021; 20(3):2725. (In Russ.) doi:10.15829/1728-8800-2021-2725.Liao R, Li Z, Wang Q, et al. Revascularization of chronic total occlusion coronary artery and cardiac regeneration. Front Cardiovasc Med. 2022;9:940808. doi:10.3389/fcvm.2022.940808.Liao R, Li Z, Wang Q, et al. Revascularization of chronic total occlusion coronary artery and cardiac regeneration. Front Cardiovasc Med. 2022;9:940808. doi:10.3389/fcvm.2022.940808.Fei Y, Hou J, Xuan W, et al. The relationship of plasma miR-503 and coronary collateral circulation in patients with coronary artery disease. Life Sci. 2018;207:145-51. doi:10.1016/j.lfs.2018.06.001.Fei Y, Hou J, Xuan W, et al. The relationship of plasma miR-503 and coronary collateral circulation in patients with coronary artery disease. Life Sci. 2018;207:145-51. doi:10.1016/j.lfs.2018.06.001.Seiler C, Stoller M, Pitt B, et al. The human coronary collateral circulation: development and clinical importance. Eur Heart J. 2013;34:2674-82. doi:10.1093/eurheartj/eht195.Seiler C, Stoller M, Pitt B, et al. The human coronary collateral circulation: development and clinical importance. Eur Heart J. 2013;34:2674-82. doi:10.1093/eurheartj/eht195.Rentrop KP, Cohen M, Blanke H, et al. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol. 1985;5:587-92. doi:10.1016/s0735-1097(85)80380-6.Rentrop KP, Cohen M, Blanke H, et al. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol. 1985;5:587-92. doi:10.1016/s0735-1097(85)80380-6.Werner GS, Ferrari M, Heinke S, et al. Angiographic asses­sment of collateral connections in comparison with invasively determined collateral function in chronic coronary occlusions. Circulation. 2003;107:1972-7. doi:10.1161/01.CIR.0000061953.72662.3A.Werner GS, Ferrari M, Heinke S, et al. Angiographic asses­sment of collateral connections in comparison with invasively determined collateral function in chronic coronary occlusions. Circulation. 2003;107:1972-7. doi:10.1161/01.CIR.0000061953.72662.3A.Hakimzadeh N, Piek JJ. MicroRNAs to take the place of collateral flow index measurements and Rentrop scoring?-Reply to Papageorgiou et al. Ann Transl Med. 2016;4:297. doi:10.21037/atm.2016.07.26.Hakimzadeh N, Piek JJ. MicroRNAs to take the place of collateral flow index measurements and Rentrop scoring?-Reply to Papageorgiou et al. Ann Transl Med. 2016;4:297. doi:10.21037/atm.2016.07.26.Pijls NH, van Son JA, Kirkeeide RL, et al. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation. 1993;87:1354-67. doi:10.1161/01.CIR.87.4.1354.Pijls NH, van Son JA, Kirkeeide RL, et al. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation. 1993;87:1354-67. doi:10.1161/01.CIR.87.4.1354.Seiler C, Fleisch M, Garachemani A, et al. Coronary collateral quantitation in patients with coronary artery disease using intravascular flow velocity or pressure measurements. J Am Coll Cardiol. 1998;32:1272-9. doi:10.1016/s0735-1097(98)00384-2.Seiler C, Fleisch M, Garachemani A, et al. Coronary collateral quantitation in patients with coronary artery disease using intravascular flow velocity or pressure measurements. J Am Coll Cardiol. 1998;32:1272-9. doi:10.1016/s0735-1097(98)00384-2.Бадоян А. Г., Горгулько А. П., Хелимский Д. А. и др. Роль коллатерального кровообращения в поддержании и восстановлении функции миокарда левого желудочка и современные методы его оценки. Российский кардиологический журнал. 2022;27(8):5164. doi:10.15829/1560-4071-2022-5164.Badoyan AG, Gorgulko AP, Khelimsky DA, et al. Role of collateral circulation in maintaining and restoring the left ventricular function and modern methods for its assessment. Russian Journal of Cardiology. 2022;27(8):5164. (In Russ.) doi:10.15829/1560-4071-2022-5164.Elsman P, van ’t Hof AWJ, de Boer MJ, et al. Role of collateral circulation in the acute phase of ST-segment-elevation myocardial infarction treated with primary coronary intervention. Eur Heart J. 2004;25:854-8. doi:10.1016/j.ehj.2004.03.005.Elsman P, van ’t Hof AWJ, de Boer MJ, et al. Role of collateral circulation in the acute phase of ST-segment-elevation myocardial infarction treated with primary coronary intervention. Eur Heart J. 2004;25:854-8. doi:10.1016/j.ehj.2004.03.005.Wang J, Yan Y, Song D, et al. Reduced plasma miR-146a is a predictor of poor coronary collateral circulation in patients with coronary artery disease. Biomed Res Int. 2016;2016:4285942. doi:10.1155/2016/4285942.Wang J, Yan Y, Song D, et al. Reduced plasma miR-146a is a predictor of poor coronary collateral circulation in patients with coronary artery disease. Biomed Res Int. 2016;2016:4285942. doi:10.1155/2016/4285942.Searles CD. MicroRNAs and Cardiovascular Disease Risk. Curr Cardiol Rep. 2024;26:51-60. doi:10.1007/s11886-023-02014-1.Searles CD. MicroRNAs and Cardiovascular Disease Risk. Curr Cardiol Rep. 2024;26:51-60. doi:10.1007/s11886-023-02014-1.Fazmin IT, Achercouk Z, Edling CE, et al. Circulating microRNA as a Biomarker for Coronary Artery Disease. Biomolecules. 2020;10:1354. doi:10.3390/biom10101354.Fazmin IT, Achercouk Z, Edling CE, et al. Circulating microRNA as a Biomarker for Coronary Artery Disease. Biomolecules. 2020;10:1354. doi:10.3390/biom10101354.Zhelankin AV, Stonogina DA, Vasiliev SV, et al. Circulating Extra­cellular miRNA Analysis in Patients with Stable CAD and Acute Coronary Syndromes. Biomolecules. 2021;11:962. doi:10.3390/biom11070962.Zhelankin AV, Stonogina DA, Vasiliev SV, et al. Circulating Extra­cellular miRNA Analysis in Patients with Stable CAD and Acute Coronary Syndromes. Biomolecules. 2021;11:962. doi:10.3390/biom11070962.Khan J, Lieberman JA, Lockwood CM. Variability in, variability out: best practice recommendations to standardize pre-analy­tical variables in the detection of circulating and tissue micro­RNAs. Clin Chem Lab Med. 2017;55:608-21. doi:10.1515/cclm-2016-0471.Khan J, Lieberman JA, Lockwood CM. Variability in, variability out: best practice recommendations to standardize pre-analy­tical variables in the detection of circulating and tissue micro­RNAs. Clin Chem Lab Med. 2017;55:608-21. doi:10.1515/cclm-2016-0471.Hans FP, Moser M, Bode C, et al. MicroRNA regulation of angio­genesis and arteriogenesis. Trends Cardiovasc Med. 2010;20: 253-62. doi:10.1016/j.tcm.2011.12.001.Hans FP, Moser M, Bode C, et al. MicroRNA regulation of angio­genesis and arteriogenesis. Trends Cardiovasc Med. 2010;20: 253-62. doi:10.1016/j.tcm.2011.12.001.Raitoharju E, Lyytikäinen L-P, Levula M, et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis. 2011;219:211-7. doi:10.1016/j.atherosclerosis.2011.07.020.Raitoharju E, Lyytikäinen L-P, Levula M, et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis. 2011;219:211-7. doi:10.1016/j.atherosclerosis.2011.07.020.Bergami M, Fabin N, Cenko E, et al. MicroRNAs as Potential Biomarkers in Coronary Artery Disease. Curr Top Med Chem. 2023;23:454-69. doi:10.2174/1568026623666221221124530.Bergami M, Fabin N, Cenko E, et al. MicroRNAs as Potential Biomarkers in Coronary Artery Disease. Curr Top Med Chem. 2023;23:454-69. doi:10.2174/1568026623666221221124530.Zhu L-P, Zhou J-P, Zhang J-X, et al. MiR-15b-5p Regulates Collateral Artery Formation by Targeting AKT3 (Protein Kinase B-3). Arterioscler Thromb Vasc Biol. 2017;37:957-68. doi:10.1161/ATVBAHA.116.308905.Zhu L-P, Zhou J-P, Zhang J-X, et al. MiR-15b-5p Regulates Collateral Artery Formation by Targeting AKT3 (Protein Kinase B-3). Arterioscler Thromb Vasc Biol. 2017;37:957-68. doi:10.1161/ATVBAHA.116.308905.Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545-50. doi:10.1073/pnas.0506580102.Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545-50. doi:10.1073/pnas.0506580102.Gene Ontology Consortium, Aleksander SA, Balhoff J, et al. The Gene Ontology knowledgebase in 2023. Genetics. 2023;224: iyad031. doi:10.1093/genetics/iyad031.Gene Ontology Consortium, Aleksander SA, Balhoff J, et al. The Gene Ontology knowledgebase in 2023. Genetics. 2023;224: iyad031. doi:10.1093/genetics/iyad031.Kanehisa M, Furumichi M, Sato Y, et al. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:D587-92. doi:10.1093/nar/gkac963.Kanehisa M, Furumichi M, Sato Y, et al. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:D587-92. doi:10.1093/nar/gkac963.Nie X, Su L, Zhou Y, et al. Association between plasma levels of microRNA-126 and coronary collaterals in patients with coronary artery disease. Zhonghua Xin Xue Guan Bing Za Zhi. 2014;42:561-5. doi:10.3760/cma.j.issn.0253-3758.2014.07.008.Nie X, Su L, Zhou Y, et al. Association between plasma levels of microRNA-126 and coronary collaterals in patients with coronary artery disease. Zhonghua Xin Xue Guan Bing Za Zhi. 2014;42:561-5. doi:10.3760/cma.j.issn.0253-3758.2014.07.008.Gacoń J, Kabłak-Ziembicka A, Stępień E, et al. Decision-making microRNAs (miR-124, -133a/b, -34a and -134) in patients with occluded target vessel in acute coronary syndrome. Kardiol Pol. 2015;74:280-8. doi:10.5603/KP.a2015.0174.Gacoń J, Kabłak-Ziembicka A, Stępień E, et al. Decision-making microRNAs (miR-124, -133a/b, -34a and -134) in patients with occluded target vessel in acute coronary syndrome. Kardiol Pol. 2015;74:280-8. doi:10.5603/KP.a2015.0174.Hou S, Fang M, Zhu Q, et al. MicroRNA-939 governs vascular integrity and angiogenesis through targeting γ-catenin in endothelial cells. Biochem Biophys Res Commun. 2017;484:27-33. doi:10.1016/j.bbrc.2017.01.085.Hou S, Fang M, Zhu Q, et al. MicroRNA-939 governs vascular integrity and angiogenesis through targeting γ-catenin in endothelial cells. Biochem Biophys Res Commun. 2017;484:27-33. doi:10.1016/j.bbrc.2017.01.085.Wang J, Yan Y, Song D, et al. The association of plasma miR-155 and VCAM-1 levels with coronary collateral circulation. Biomark Med. 2017;11:125-31. doi:10.2217/bmm-2016-0282.Wang J, Yan Y, Song D, et al. The association of plasma miR-155 and VCAM-1 levels with coronary collateral circulation. Biomark Med. 2017;11:125-31. doi:10.2217/bmm-2016-0282.Gao W, Li C, Yuan J, et al. Circ-MBOAT2 regulates angiogenesis via the miR-495/NOTCH1 axis and associates with myocardial perfusion in patients with coronary chronic total occlusion. Int J Mol Sci. 2024;25:793. doi:10.3390/ijms25020793.Gao W, Li C, Yuan J, et al. Circ-MBOAT2 regulates angiogenesis via the miR-495/NOTCH1 axis and associates with myocardial perfusion in patients with coronary chronic total occlusion. Int J Mol Sci. 2024;25:793. doi:10.3390/ijms25020793.Киселева А. В., Васильев Д. К., Сопленкова А. Г. и др. Ассоциация уровней циркулирующих микроРНК плазмы с различной выраженностью коллатерального кровообращения при хронической окклюзии коронарной артерии у пациентов с ишемической болезнью сердца: пилотное исследование. Кардиоваскулярная терапия и профилактика. 2024;23(7):4086. doi:10.15829/1728-8800-2024-4086.Kiseleva AV, Vasilyev DK, Soplenkova AG, et al. Association of plasma microRNA levels with different collateral circulation degree in chronic total occlusion patients with coronary artery disease: a pilot study. Cardiovascular Therapy and Prevention. 2024;23(7):4086. (In Russ.) doi:10.15829/1728-8800-2024-4086.Wong RKY, MacMahon M, Woodside JV, et al. A comparison of RNA extraction and sequencing protocols for detection of small RNAs in plasma. BMC Genomics. 2019;20:446. doi:10.1186/s12864-019-5826-7.Wong RKY, MacMahon M, Woodside JV, et al. A comparison of RNA extraction and sequencing protocols for detection of small RNAs in plasma. BMC Genomics. 2019;20:446. doi:10.1186/s12864-019-5826-7.Brunet-Vega A, Pericay C, Quílez ME, et al. Variability in microRNA recovery from plasma: Comparison of five commercial kits. Anal Biochem. 2015;488:28-35. doi:10.1016/j.ab.2015.07.018.Brunet-Vega A, Pericay C, Quílez ME, et al. Variability in microRNA recovery from plasma: Comparison of five commercial kits. Anal Biochem. 2015;488:28-35. doi:10.1016/j.ab.2015.07.018.Chan S-F, Cheng H, Goh KK-R, et al. Preanalytic Methodological Considerations and Sample Quality Control of Circulating miRNAs. J Mol Diagn. 2023;25:438-53. doi:10.1016/j.jmoldx.2023.03.005.Chan S-F, Cheng H, Goh KK-R, et al. Preanalytic Methodological Considerations and Sample Quality Control of Circulating miRNAs. J Mol Diagn. 2023;25:438-53. doi:10.1016/j.jmoldx.2023.03.005.Zhelankin AV, Iulmetova LN, Sharova EI. The Impact of the Anticoagulant Type in Blood Collection Tubes on Circulating Extracellular Plasma MicroRNA Profiles Revealed by Small RNA Sequencing. Int J Mol Sci. 2022;23:10340. doi:10.3390/ijms231810340.Zhelankin AV, Iulmetova LN, Sharova EI. The Impact of the Anticoagulant Type in Blood Collection Tubes on Circulating Extracellular Plasma MicroRNA Profiles Revealed by Small RNA Sequencing. Int J Mol Sci. 2022;23:10340. doi:10.3390/ijms231810340.Papageorgiou N, Zacharia E, Tousoulis D. Association between microRNAs and coronary collateral circulation: is there a new role for the small non-coding RNAs? Ann Transl Med. 2016;4:223. doi:10.21037/atm.2016.05.51.Papageorgiou N, Zacharia E, Tousoulis D. Association between microRNAs and coronary collateral circulation: is there a new role for the small non-coding RNAs? Ann Transl Med. 2016;4:223. doi:10.21037/atm.2016.05.51.İleri M, Güray Ü, Yetkin E, et al. A new risk scoring model for prediction of poor coronary collateral circulation in acute non-ST-elevation myocardial infarction. Cardiol J. 2016;23:107-13. doi:10.5603/CJ.a2015.0064.İleri M, Güray Ü, Yetkin E, et al. A new risk scoring model for prediction of poor coronary collateral circulation in acute non-ST-elevation myocardial infarction. Cardiol J. 2016;23:107-13. doi:10.5603/CJ.a2015.0064.Jansen F, Yang X, Hoelscher M, et al. Endothelial Microparticle–Mediated Transfer of MicroRNA-126 Promotes Vascular Endothelial Cell Repair via SPRED1 and Is Abrogated in Glucose-Damaged Endothelial Microparticles. Circulation. 2013;128:2026-38. doi:10.1161/CIRCULATIONAHA.113.001720.Jansen F, Yang X, Hoelscher M, et al. Endothelial Microparticle–Mediated Transfer of MicroRNA-126 Promotes Vascular Endothelial Cell Repair via SPRED1 and Is Abrogated in Glucose-Damaged Endothelial Microparticles. Circulation. 2013;128:2026-38. doi:10.1161/CIRCULATIONAHA.113.001720.de Boer HC, van Solingen C, Prins J, et al. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J. 2013;34:3451-7. doi:10.1093/eurheartj/eht007.de Boer HC, van Solingen C, Prins J, et al. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J. 2013;34:3451-7. doi:10.1093/eurheartj/eht007.Xiang M, Zeng Y, Yang R, et al. U6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem Biophys Res Commun. 2014;454:210-14. doi:10.1016/j.bbrc.2014.10.064.Xiang M, Zeng Y, Yang R, et al. U6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem Biophys Res Commun. 2014;454:210-14. doi:10.1016/j.bbrc.2014.10.064.Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997-1006. doi:10.1038/cr.2008.282.Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997-1006. doi:10.1038/cr.2008.282.Tomasetti M, Staffolani S, Nocchi L, et al. Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem. 2012;45:575-81. doi:10.1016/j.clinbiochem.2012.02.009.Tomasetti M, Staffolani S, Nocchi L, et al. Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem. 2012;45:575-81. doi:10.1016/j.clinbiochem.2012.02.009.Goeman JJ, Solari A. Multiple hypothesis testing in genomics. Stat Med. 2014;33:1946-78. doi:10.1002/sim.6082.Goeman JJ, Solari A. Multiple hypothesis testing in genomics. Stat Med. 2014;33:1946-78. doi:10.1002/sim.6082.

The authors declare that there are no conflicts of interest present.